KRYS - Krystal Biotech, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
49.41
+1.06 (+2.19%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close48.35
Open48.32
Bid45.51 x 1000
Ask49.51 x 800
Day's Range47.77 - 50.40
52 Week Range14.30 - 50.40
Volume210,298
Avg. Volume209,514
Market Cap837.183M
Beta (3Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-1.05
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est66.40
Trade prices are not sourced from all markets
  • GlobeNewswire20 days ago

    Krystal Biotech, Inc. Added to the Russell 2000 Index

    Krystal Biotech Inc., (“Krystal”) (KRYS), a gene therapy company developing medicines to treat skin diseases, today announces that it has been added to the Russell 2000® Index, effective after the stock market close on June 28, 2019 following Russell's annual reconstitution of its comprehensive set of U.S. and global equity indexes. The Russell 2000® Index measures the performance of the small-cap segment of the U.S. equity market. The index is a subset of the Russell 3000® Index and represents approximately 10 percent of the total market capitalization of that index.

  • 3 Small-Cap Biotech Stocks That Soared Last Week
    Motley Fool20 days ago

    3 Small-Cap Biotech Stocks That Soared Last Week

    It was a great week for these three stocks, but can they continue climbing?

  • Hedge Funds Have Never Been This Bullish On Krystal Biotech, Inc. (KRYS)
    Insider Monkey24 days ago

    Hedge Funds Have Never Been This Bullish On Krystal Biotech, Inc. (KRYS)

    Before putting in our own effort and resources into finding a good investment, we can quickly utilize hedge fund expertise to give us a quick glimpse of whether that stock could make for a good addition to our portfolios. The odds are not exactly stacked in investors' favor when it comes to beating the market, […]

  • Benzinga26 days ago

    Krystal Biotech Analyst Lifts Price Target More Than 50% On Positive Phase 2 Data, RMAT Designation

    Krystal Biotech Inc (NASDAQ: KRYS ) announced positive Phase 2 data for KB103 Monday and said the gene therapy received the Regenerative Medicine Advanced Therapy designation from the FDA. The Phase 2 ...

  • Benzinga26 days ago

    The Daily Biotech Pulse: Genfit NASH Drug In China, Conatus Explores Sale, Gilead Stitches Up Immuno-Oncology Partnership

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on June 24) Global Blood Therapeutics Inc (NASDAQ: GBT ) Krystal ...

  • Why NRC Group Holdings, PCM, and Krystal Biotech Jumped Today
    Motley Fool27 days ago

    Why NRC Group Holdings, PCM, and Krystal Biotech Jumped Today

    These obscure companies were some of the biggest winners on Wall Street.

  • Benzinga27 days ago

    Krystal Biotech Rallies On Positive Trial Results For Skin Condition

    Krystal Biotech Inc (NASDAQ: KRYS ) shares spiked after the gene therapy company announcing positive results from its KB103 clinical trial on Monday.  The stock was higher by 46.11% at $42.59 at the time ...

  • Krystal Biotech stock jumps after positive clinical trial results
    American City Business Journals27 days ago

    Krystal Biotech stock jumps after positive clinical trial results

    The Pittsburgh-based gene therapy company plans to launch phase three of the trial before the end of 2019.

  • MarketWatch27 days ago

    Krystal Biotech shares up 27% after company's skin drug receives expedited review designation from FDA

    Shares of Krystal Biotech Inc. were up 27% in Monday intraday trade after the gene therapy company said it had received an expedited review designation from the FDA for its lead drug candidate to treat a skin condition called dystrophic epidermolysis bullosa. The condition, which involves severe blistering due to a lack of collagen in the skin, is currently incurable. Krystal's drug, called KB102, is a viral vector that delivers human COL7A1 genes -- which code for functional collagen -- directly to the patient's cells. The company also announced some positive results from a Phase 2 trial looking at six blister wounds being treated with KB103 -- five closed up completely, and the drug was well-tolerated, Krystal said. No serious adverse events or drug-related adverse events were reported, and there were no reports of inflammation or irritation in the KB103-treated wounds, the company said. Shares of Krystal have gained 76% in the year to date, while the S&P 500 has gained 17.8%.

  • GlobeNewswire27 days ago

    Krystal Biotech Announces Positive Results from Phase 2 Clinical Trial (“GEM-2 study”) of KB103 and Receives Regenerative Medicine Advanced Therapy (“RMAT”) Designation from FDA for KB103

    With the exception of one chronic wound, the remaining KB103 treated wounds in Phase 2 trial remained 100% closed at 90 day timepoint. The duration of wound closure on two patients in Phase 1 trial as of the last follow up was 184 days (6.6 months) and 174 days (6.2 months). PITTSBURGH, June 24, 2019 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (KRYS), a gene therapy company dedicated to developing and commercializing novel treatments for patients suffering from rare dermatological diseases, today announced positive results from its Phase 2 placebo-controlled clinical trial of KB103 (GEM-2) study and an update on results from Phase 1 (GEM-1) study.

  • GlobeNewswirelast month

    Krystal Submits Investigational New Drug (IND) Application for KB105, Topical Gene Therapy Candidate for Transglutaminase-1 Deficient Autosomal Recessive Congenital Ichthyosis

    Krystal Biotech Inc., (“Krystal”) (KRYS), a gene therapy company developing medicines to treat dermatological diseases, today announces that it has submitted an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) to initiate a Phase 1/2, first in-human trial of KB105, an HSV-1 based gene therapy engineered to deliver a human transglutaminase-1 (TGM1) gene to patients with TGM1-deficient autosomal recessive congenital ichthyosis (ARCI). TGM1-deficient ARCI is a debilitating rare skin disease characterized by excessive, thick scaling of the skin and causing multiple chronic health conditions.

  • GlobeNewswire2 months ago

    Krystal Biotech to Present at the RBC Capital Markets 2019 Healthcare Conference

    PITTSBURGH, May 15, 2019 -- Krystal Biotech Inc., (“Krystal”) (NASDAQ: KRYS), a gene therapy company developing medicines to treat dermatological diseases, today announced that.

  • GlobeNewswire2 months ago

    Krystal Biotech Reports First Quarter 2019 Financial Results and Provides Corporate Update

    Krystal Biotech Inc., (“Krystal”) (KRYS), a gene therapy company developing medicines to treat dermatological diseases, announced financial results for first quarter 2019 and an update on its business progress. “We are very pleased to have KB103 accepted into the PRIME program and believe that KB103 could potentially be a transformative treatment option for patients with dystrophic epidermolysis bullosa,” said Krish S. Krishnan, chairman and chief executive officer.

  • GlobeNewswire3 months ago

    Krystal Biotech Announces Five Presentations of Clinical and Preclinical Data at the Society for Investigative Dermatology Annual Meeting

    PITTSBURGH, April 29, 2019 -- Krystal Biotech Inc., (“Krystal”) (NASDAQ: KRYS), a gene therapy company developing medicines to treat rare skin diseases announces presentations.

  • GlobeNewswire4 months ago

    EMA Grants PRIME Eligibility for KB103 to Treat Dystrophic Epidermolysis Bullosa

    Krystal Biotech Inc., (“Krystal”) (KRYS), a gene therapy company developing medicines to treat dermatological diseases, announced today that the European Medicines Agency (EMA) has granted access to its PRIME (PRIority MEdicines) scheme for KB103 (bercolagene telserpavec), a first-in-class topical gene therapy for the treatment of dystrophic epidermolysis bullosa (DEB).

  • GlobeNewswire4 months ago

    Krystal Biotech Reports 2018 Financial Results and Business Progress

    Ancoris, a cGMP facility for clinical and commercial production of KB103, is operational following successful completion of a trial run. PITTSBURGH, March 12, 2019 (GLOBE NEWSWIRE) -- Krystal Biotech Inc., (“Krystal”) (KRYS), a gene therapy company developing medicines to treat dermatological diseases announced financial results for 2018 and an update on its business progress. Commenting on the year, Krish S. Krishnan, chairman and chief executive officer, said, “2018 was a productive year for Krystal as we worked to become fully-integrated in the gene therapy space.

  • Krystal (KRYS) in Focus: Stock Moves 5.1% Higher
    Zacks4 months ago

    Krystal (KRYS) in Focus: Stock Moves 5.1% Higher

    Krystal (KRYS) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.

  • GlobeNewswire5 months ago

    Krystal Biotech Continues Vertical Integration with Official Inauguration of Ancoris Gene Therapy Manufacturing Facility at its Pittsburgh Headquarters

    Krystal Biotech Inc., (“Krystal”) (KRYS), a gene therapy company developing medicines to treat dermatological diseases, announced today official opening of Ancoris, its new cGMP facility for clinical and commercial manufacture of its lead product KB103, following a successful trial run and the official inaugural ribbon cutting ceremony, held in Pittsburgh on March 5, 2019. The ribbon cutting ceremony was attended by City of Pittsburgh Mayor William Peduto, representatives from the Office of U.S. Senator Patrick J. Toomey and U. S. Senator Robert P. Casey, and Brett Kopelan, executive director of debra of America, a nonprofit organization providing all-inclusive support to the epidermolysis bullosa (EB) community.

  • GlobeNewswire5 months ago

    Krystal Strengthens Board of Directors with Appointment of Julian S. Gangolli

    Krystal Biotech Inc., (Krystal) (KRYS), a gene therapy company developing “off-the-shelf” treatments for rare dermatological diseases, announced that Julian S. Gangolli has been elected to Krystal’s Board of Directors and will serve as a member of the Nomination and Governance Committee, effective March 1, 2019. The appointment will increase the size of the Krystal Board of Directors to seven members. “Julian has a distinguished track record of successfully overseeing product commercialization launches in dermatology, rare disease and multiple other disease states, and will be an outstanding addition to our board,” said Krish S. Krishnan, chairman and chief executive officer of Krystal.

  • GlobeNewswire5 months ago

    Krystal Biotech to Present at the Cowen and Company 39th Annual Health Care Conference

    PITTSBURGH, March 01, 2019 -- Krystal Biotech Inc., (“Krystal”) (NASDAQ: KRYS), a gene therapy company dedicated to developing and commercializing novel treatments for patients.

  • GlobeNewswire5 months ago

    Krystal Biotech to Present at the 8th Annual SVB Leerink Global Healthcare Conference

    PITTSBURGH, Feb. 22, 2019 --  Krystal Biotech Inc., (“Krystal”) (NASDAQ: KRYS), a gene therapy company dedicated to developing and commercializing novel treatments for patients.

  • Danforth Advisors entering Pittsburgh, focusing on life sciences sector
    American City Business Journals6 months ago

    Danforth Advisors entering Pittsburgh, focusing on life sciences sector

    Danforth Advisors, a Boston-area provider of financial and accounting services to the life sciences sector, has entered Pittsburgh. Founded in 2011, Danforth employs a team of consultants who are experienced accountants, corporate controllers and chief financial officers and specialists in financial planning and analysis. “Biotech companies are often pre-revenue stage and trying to build a business focused on science and getting things into the clinics,” said Robert Dickey IV, who joined Danforth last summer as managing director, Mid-Atlantic Region.

  • GlobeNewswire6 months ago

    Krystal Biotech Completes Construction of Ancoris - A New GMP Facility for Commercial Manufacturing of a Viral Vector-Based Gene Therapy to Treat Dystrophic Epidermolysis Bullosa

    Krystal Biotech Inc., (“Krystal”) (KRYS), a gene therapy company developing topical and intradermal "off-the-shelf" treatments for rare dermatological diseases, today announces that construction of Ancoris, a new state-of-the-art Good Manufacturing Practice (GMP) facility, is complete. The new facility is located near the Company’s headquarters in Pittsburgh and will support clinical and commercial manufacturing of Krystal’s lead product candidate, KB103, for the treatment of dystrophic epidermolysis bullosa (DEB). “Our development of internal manufacturing capabilities bolsters our position for commercial readiness as we execute on our vision to bring our therapies to the patient communities in need,” said Krish S Krishnan, chairman and chief executive officer of Krystal Biotech.

  • GlobeNewswire7 months ago

    Krystal Biotech Completes Dosing in the GEM-Phase 2 Study in Pediatric Patients for the Treatment of Dystrophic Epidermolysis Bullosa

    PITTSBURGH, Dec. 19, 2018 -- Krystal Biotech Inc., (“Krystal”) (NASDAQ: KRYS), a gene therapy company developing topical and intradermal "off-the-shelf" treatments for rare.

  • GlobeNewswire8 months ago

    New Research Coverage Highlights VSE, Weyco Group, Funko, B. Riley Financial, Krystal Biotech, and Xcel Brands — Consolidated Revenues, Company Growth, and Expectations for 2018

    NEW YORK, Nov. 21, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.